D. Florinskiy, A. Pshonkin, A. V. Poletaev, E. Seregina, Elena M Sysoeva, I. Yunusova, P. Zharkov
Abstract
This article describes the clinical presentation, phenotype, and bleeding in a patient with type 3 von Willebrand disease and alloantibodies, as well as off-label therapy with emicizumab. Keywords: Inhibitor, von Willebrand disease, prophylactic treatment, factor Willebrand concentrate, children, Emicizumab
Citation format
FLORINSKIY, D., et al. A clinical case of inhibitor development to von willebrand factor in a patient with von willebrand disease type III and treatment with emicizumab. Pediatric Hematology/Oncology and Immunopathology, 2026.